Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

被引：12

作者：

Badros, Ashraf Z. ^{[1
]}

Ma, Ning ^{[1
]}

Rapoport, Aaron P. ^{[1
]}

Lederer, Emily ^{[1
]}

Lesokhin, Alexander M. ^{[2
,3
]}

机构：

[1] Univ Maryland, Greenebaum Comprehens Canc Ctr, 22 South Greene St, Baltimore, MD 21201 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, New York, NY USA

来源：

BLOOD ADVANCES | 2019年 / 3卷 / 11期

关键词：

IMMUNOTHERAPY;

D O I：

10.1182/bloodadvances.2019000191

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1658 / 1660

页数：3

共 10 条

[1] Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity [J].

Anagnostou, Valsamo ;

Yarchoan, Mark ;

Hansen, Aaron R. ;

Wang, Hao ;

Verde, Franco ;

Sharon, Elad ;

Collyar, Deborah ;

Chow, Laura Q. M. ;

Forde, Patrick M. .

CLINICAL CANCER RESEARCH, 2017, 23 (17) :4959-4969

[2]

[Anonymous], 2018, J CLIN ONCOL S

[3]

[Anonymous], 2018, J CLIN ONCOL S

[4] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma [J].

Badros, Ashraf ;

Hyjek, Elizabeth ;

Ma, Ning ;

Lesokhin, Alexander ;

Dogan, Ahmet ;

Rapoport, Aaron P. ;

Kocoglu, Mehmet ;

Lederer, Emily ;

Philip, Sunita ;

Milliron, Todd ;

Dell, Cameron ;

Goloubeva, Olga ;

Singh, Zeba .

BLOOD, 2017, 130 (10) :1189-1197

[5] Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care [J].

Ben-Aharon, Omer ;

Magnezi, Racheli ;

Leshno, Moshe ;

Goldstein, Daniel A. .

JAMA ONCOLOGY, 2018, 4 (03) :326-332

[6] Do immune checkpoint inhibitors need new studies methodology? [J].

Ferrara, Roberto ;

Pilotto, Sara ;

Caccese, Mario ;

Grizzi, Giulia ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Milella, Michele ;

Besse, Benjamin ;

Tortora, Giampaolo ;

Bria, Emilio .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S1564-S1580

[7] Immunotherapy Combinations in Multiple Myeloma - Known Unknowns [J].

Gormley, Nicole J. ;

Pazdur, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19) :1791-1795

[8] Medians and Milestones in Describing the Path to Cancer Cures Telling "Tails" [J].

Hellmann, Matthew D. ;

Kris, Mark G. ;

Rudin, Charles M. .

JAMA ONCOLOGY, 2016, 2 (02) :167-168

[9] Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma [J].

Manson, Guillaume ;

Herbaux, Charles ;

Brice, Pauline ;

Bouabdallah, Krimo ;

Stamatoullas, Aspasia ;

Schiano, Jean-Marc ;

Ghesquieres, Herve ;

Dercle, Laurent ;

Houot, Roch .

BLOOD, 2018, 131 (25) :2856-2859

[10] Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma [J].

Robert, Caroline ;

Ribas, Antoni ;

Hamid, Omid ;

Daud, Adil ;

Wolchok, Jedd D. ;

Joshua, Anthony M. ;

Hwu, Wen-Jen ;

Weber, Jeffrey S. ;

Gangadhar, Tara C. ;

Joseph, Richard W. ;

Dronca, Roxana ;

Patnaik, Amita ;

Zarour, Hassane ;

Kefford, Richard ;

Hersey, Peter ;

Zhang, Jin ;

Anderson, James ;

Diede, Scott J. ;

Ebbinghaus, Scot ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1668-+

← 1 →